Izotropic Corporation (IZOZF)
USD 0.03
(-10.45%)
USD 0.03
(-10.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.6 Million CAD | 69.3% |
| 2023 | -5.22 Million CAD | 19.62% |
| 2022 | -6.34 Million CAD | -32.79% |
| 2021 | -4.82 Million CAD | -331.6% |
| 2020 | -1.07 Million CAD | -194.02% |
| 2019 | -311.01 Thousand CAD | 44.07% |
| 2018 | -594.37 Thousand CAD | -864.21% |
| 2017 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -230.54 Thousand CAD | 65.7% |
| 2024 FY | - CAD | 69.11% |
| 2024 Q4 | -322.76 Thousand CAD | -40.0% |
| 2024 Q1 | -415.36 Thousand CAD | 67.25% |
| 2024 Q2 | -672.06 Thousand CAD | -71.42% |
| 2023 Q3 | -1.9 Million CAD | -47.8% |
| 2023 Q4 | -1.19 Million CAD | 37.22% |
| 2023 FY | - CAD | 19.62% |
| 2023 Q1 | -961.54 Thousand CAD | 40.74% |
| 2023 Q2 | -1.29 Million CAD | -34.18% |
| 2022 Q2 | -2.52 Million CAD | -106.58% |
| 2022 Q1 | -1.22 Million CAD | 35.76% |
| 2022 FY | - CAD | -32.79% |
| 2022 Q4 | -1.62 Million CAD | -30.65% |
| 2022 Q3 | -1.24 Million CAD | 50.87% |
| 2021 Q3 | -2.37 Million CAD | -539.27% |
| 2021 Q2 | -370.9 Thousand CAD | 17.28% |
| 2021 FY | - CAD | -331.6% |
| 2021 Q1 | -448.4 Thousand CAD | 25.8% |
| 2021 Q4 | -1.9 Million CAD | 19.66% |
| 2020 FY | - CAD | -194.02% |
| 2020 Q4 | -604.33 Thousand CAD | -143.61% |
| 2020 Q3 | -248.07 Thousand CAD | -60.5% |
| 2020 Q1 | -145.59 Thousand CAD | -6.27% |
| 2020 Q2 | -154.56 Thousand CAD | -6.16% |
| 2019 Q1 | -86.26 Thousand CAD | 43.61% |
| 2019 Q2 | -92.74 Thousand CAD | -7.51% |
| 2019 Q4 | -137 Thousand CAD | -80.32% |
| 2019 FY | - CAD | 44.07% |
| 2019 Q3 | -75.98 Thousand CAD | 18.08% |
| 2018 Q1 | -72.07 Thousand CAD | -257676.9% |
| 2018 Q2 | -408.66 Thousand CAD | -466.99% |
| 2018 Q3 | -67.15 Thousand CAD | 83.57% |
| 2018 Q4 | -152.96 Thousand CAD | -127.77% |
| 2018 FY | - CAD | -864.21% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q4 | -27.96 CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -37.812% |
| Arrayit Corporation | -3.07 Million USD | 47.92% |
| Atlantic International Corp. | -5.38 Million USD | 70.262% |
| Biocept, Inc. | -30.24 Million USD | 94.7% |
| Bioqual, Inc. | 3.03 Million USD | 152.857% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -111.62% |
| DermTech, Inc. | -97.89 Million USD | 98.363% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.055% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 92.082% |
| iMD Companies, Inc. | -154.65 Thousand USD | -936.318% |
| IDenta Corp. | 71.58 Thousand USD | 2338.897% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 141.771% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 4242.567% |
| InVitro International | 6680.00 USD | 24093.398% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 70.516% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -13108.826% |
| Medical Imaging Corp. | -896.74 Thousand USD | -78.731% |
| NovelStem International Corp. | -3.78 Million USD | 57.664% |
| Optigenex Inc. | -1.18 Million USD | -35.057% |
| PharmChem, Inc. | 1.05 Million USD | 252.092% |
| Proteome Sciences plc | -1.13 Million USD | -40.964% |
| Response Genetics, Inc | -19.66 Million USD | 91.85% |
| Rennova Health, Inc. | -234.81 Thousand USD | -582.562% |
| RushNet, Inc. | -614.85 Thousand USD | -160.674% |
| ScreenPro Security Inc. | -3.43 Million USD | 53.339% |
| Stella Diagnostics Inc. | -5.7 Million USD | 71.918% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 84.394% |
| Todos Medical Ltd. | -9.39 Million USD | 82.938% |